Analysis of adverse events after anthrax immunization in US army medical personnel

Journal of Occupational and Environmental Medicine

Volumn 45, Issue 3, 2003, Pages 222-233

  Wasserman, Glenn M ^a   Grabenstein, John D ^b   Pittman, Phillip R ^c   Rubertone, Mark V ^d   Gibbs, Paul P ^c   Wang, Linda Z ^e   Golder, Lance G ^f  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

^b Anthrax Vacc Immun Program Agy   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d U S ARMY CENTER FOR HEALTH PROMOTION AND PREVENTIVE MEDICINE   (United States)

^e NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^f US Army Pacific Regional Medical Command   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTHRAX VACCINE ADSORBED; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; ANTHRAX; ARMY; ARTHRALGIA; ARTICLE; CHILL; COHORT ANALYSIS; DIARRHEA; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HEALTH HAZARD; HEALTH PROGRAM; HEALTH SURVEY; HOSPITALIZATION; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; MEDICAL PERSONNEL; MYALGIA; NAUSEA; OCCUPATIONAL HEALTH; OUTPATIENT CARE; PRURITUS; VOMITING;

ADULT; AMBULATORY CARE; ANTHRAX; ANTHRAX VACCINES; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MILITARY PERSONNEL; UNITED STATES; VACCINATION;

ANTHRAX;

EID: 0037343678     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jom.0000058345.05741.6b     Document Type: Article

References (36)

1. Pile JC, Malone JD, Eitzen EM, et al. Anthrax as a potential biological warfare agent. Arch Intern Med. 1998;158:429-434.
2. Zilinskas RA. Iraq's biological weapons: the past as future? JAMA. 1997;278:418-424.
3. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA. 1999;28118:1735-1745.
4. Mazzuchi JF, Claypool RG, Hyams KC, et al. Protecting the health of US military forces: a national obligation. Aviat Space Environ Med. 2000;713:260-265.
5. Klietmann WF, Ruoff KL. Bioterrorism: implications for the clinical microbiologist. Clin Microbiol Rev. 2001;14:364-381.
6. Miller J. Nuclear Anxieties in a New World. New York Times (Travel). February 5, 2000.
7. Cole LA. The spector of biological weapons. Sci Am. 1996;Dec:60-65.
8. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science. 1994;2665188: 1202-1208.
9. Davis CJ: Nuclear blindness: an overview of the biological weapons programs of the former Soviet Union and Iraq. Emerg Infect Dis. 1999;5:509-512.
10. Centers for Disease Control and Prevention. Investigation of bioterrorism-related anthrax - Connecticut, 2001. MMWR. 2001;50:1077-1079.
11. Brachman PS, Gold H, Plotkin SA, et al. Field evaluation of a human anthrax vaccine. Am J Public Health. 1962;52:432-445.
12. Brachman PS, Kaufmann AF, Dalldorf FG. Industrial inhalation anthrax. Bact Rev. 1966;30:646-659.
13. Food and Drug Administration. Biological products: bacterial vaccines and toxoids, Implementation of efficacy review. Fed Reg. 1985;50:51002-51117.
14. Demicheli V, Rivetti D, Deeks JJ, et al. The effectiveness and safety of vaccines against human anthrax: a systematic review. Vaccine. 1998;16:880-884.
15. Advisory Committee on Immunization Practices. Use of anthrax vaccine in the United States. MMWR. 2000;49:1-20.
16. Sever JL, Brenner AL, Gale AD, et al. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol. Drug Safety. 2002;11:189-202.
17. Garrett L. A healthy shot of distrust/military's disclosures, decree on anthrax vaccine sparks criticism. Newsday (Health and Discovery). May 4, 1999:C8.
18. United States Army Regulation 40-562, Navy Bureau of Medicine & Surgery Instruction 6230.15, Air Force Joint Instruction 48-110, CGCIM. Immunizations & Chemoprophylaxis. Washington, DC, November 1, 1995.
19. BioPort Corporation product labeling. Anthrax vaccine adsorbed., Lansing, Michigan, January 31, 2002.
20. Title 32 Code of Federal Regulations, section 219.
21. Singleton JA, Lloyd JC, Mootrey GT, et al. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. VAERS Working Group. Vaccine. 1999;1722:2908-2917.
22. Grayson K, Brustrom JE. Health survey reliability in an active duty population. Mil Med. 2001;166:632-636.
23. Joseph SC. Policy for TRICARE Health Enrollment Assessment Review (HEAR) survey. Memorandum from Assistant Secretary of Defense Health Affairs through the Surgeon Generals of the Army, Navy, and Air Force to TRICARE Lead Agents. Health Affairs Policy 97-003.
24. Brundage JF, Kohlhase KF, Rubertone MV. Hospitalizations for all causes of US military service members in relation to participation in Operations Joint Endeavor and Joint Guard, Bosnia-Herzegovina, January 1995 to December 1997. Mil Med. 2000;1657:505-511.
25. st ed. Cary, NC: SAS Institute Inc.; 1990.
26. Gunzenhauser JD, Cook JE, Parker ME, et al. Acute side effects of anthrax vaccine in ROTC cadets participating in advanced camp, Fort Lewis, 2000. Med Surveillance Monthly Rep. 2001;7:9-14.
27. Pittman PR, Kim-Ahn G, Pifat DY, et al. Anthrax vaccine: safety and immunogenicity of a dose-reduction, route comparison study in humans. Vaccine. 2002;20: 1412-1420.
28. Institute of Medicine Committee to Assess the Safety and Efficacy of the Anthrax Vaccine. The Anthrax Vaccine: Is It Safe? Does It Work? Washington, DC: National Academy Press; 2002.
29. Centers for Disease Control and Prevention. Surveillance for adverse events associated with anthrax vaccination - US Department of Defense, 1998-2000. MMWR, 2000;49:341-345.
30. Pittman PR, Gibbs PH, Cannon TL, et al. Anthrax vaccine: short-term safety experience in humans. Vaccine. 2001;20:972- 978.
31. Treanor JJ. Adverse reactions following vaccination of adults. Commissioned paper. Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Institute of Medicine, Washington, DC; 2002.
32. Grabenstein JD. ImmunoFacts: Vaccines & Immunologic Drugs, 27th ed. St. Louis, MO: Facts and Comparisons, Inc.; August 2002.
33. Sato PA, Reed RJ, Smith TC, et al. DOD-wide medical surveillance for potential long-term adverse events associated with anthrax immunizations: hospitalizations. Vaccine. 2002;20:2369-2375.
34. Centers for Disease Control and Prevention. Application and report on manufacture of anthrax protective antigen, aluminum hydroxide adsorbed (DBS-IND 180). Observational study. Atlanta, GA: Centers for Disease Control and Prevention; 1967-1971.
35. Sato PA, Reed RJ, Smith TC, et al. Monitoring anthrax vaccine safety in U. S. military service members on active duty: surveillance of 1998 hospitalizations in temporal association with anthrax immunization. Vaccine. 2002;20:2369-2374.
36. Rehme PA, Williams R, Grabenstein JD. Ambulatory medical visits among anthrax vaccinated and unvaccinated personnel after return from southwest Asia. Mil Med. 2002;167:205-210.